In fact, the U.S. Food and Drug Administration (FDA) approved Epidiolex (a drug made with a purified form of CBD oil) in June 2018 for the treatment of seizures associated with two rare and severe forms of epilepsy in patients 2 years of age and older. These two epilepsy forms are known as Lennox-Gastaut syndrome and Dravet syndrome. Epidiolex is the first FDA-approved drug that contains a purified drug substance derived from marijuana.
It’s fair to say that the CBD market is thriving. According to market intelligence company Hemp Business Journal, $130 million worth of products containing the cannabinoid were bought in the U.S. in 2016. And that figure is only set to rise in the years to come, the data analyst believes. Indeed, the source estimates that consumer sales of CBD goods will total an astounding $2.1 billion by 2020 – buoyed, perhaps, by claims that the usage of such products can help alleviate the symptoms of chronic pain, depression and diabetes, to name but a few conditions.
Third-Party Testing: Once a CBD oil is manufactured, CBD oil companies will often submit their products for third-party tests, which are conducted by non-company personnel to ensure the product is safe for public consumption and meets quality standards.CBD oils should always be accompanied with information about third-party tests; best practice is to avoid oils that do not supply these details.